Stryker Agrees to Buy Amplitude Vascular Systems for IVL Tech

Why It Matters

By securing Amplitude’s IVL platform, Stryker can capture a larger share of the fast‑growing calcified‑lesion treatment market and challenge entrenched rivals, driving future revenue growth.

Key Takeaways

• Stryker to acquire Amplitude for $1.5 billion cash deal
• Acquisition expands Stryker’s IVL portfolio beyond peripheral arteries
• Adds FDA‑cleared IVL catheter for coronary interventions
• Strengthens competition with Philips and Boston Scientific in lithotripsy
• Expected closing Q4 2026, subject to regulatory approval

Pulse Analysis

Intravascular lithotripsy has emerged as a breakthrough solution for patients with heavily calcified arterial disease, allowing physicians to fracture calcium deposits without the need for high‑pressure balloons. Amplitude Vascular’s platform, already cleared for peripheral use, recently demonstrated safety and efficacy in coronary applications, a segment projected to exceed $2 billion in annual sales by 2030. Stryker’s acquisition not only adds a proven IVL system to its lineup but also provides a pipeline of next‑generation catheters that could accelerate adoption across interventional cardiology labs.

Stryker’s strategic rationale centers on diversifying beyond orthopedics and expanding its cardiovascular footprint. The company has invested heavily in imaging and structural heart devices, yet the IVL market remains relatively fragmented, dominated by Philips’ Shockwave and Boston Scientific’s peripheral IVL offerings. By integrating Amplitude’s technology, Stryker gains a competitive edge in both peripheral and coronary segments, positioning itself to capture cross‑sell opportunities and improve procedural efficiency for clinicians. The cash‑heavy transaction also signals confidence in the long‑term reimbursement outlook for IVL, as Medicare and private insurers increasingly recognize its clinical benefits.

Financial analysts view the $1.5 billion price tag as a fair premium given Amplitude’s recent FDA approvals and growing pipeline. The deal is expected to be accretive to Stryker’s earnings within two years, assuming successful integration and market penetration. Regulatory clearance will be the final hurdle, but with a clear path for coronary indications, the acquisition could reshape the competitive dynamics of the cardiovascular device market, driving innovation and potentially lowering costs for patients with complex calcified lesions.